The Globe and Mail reports in its Saturday, March 28, edition that Johnson & Johnson has been a top performer over the past year for Mackenzie Investments money manager Katherine Owen. The Globe's Brenda Bouw writes that Mackenzie has owned the stock for about a decade. Ms. Owen says, "It's one of our largest positions. ... We bought more of the company's shares last year after it spun off its slower-growth, lower-return consumer health business [Kenvue Inc. became a separate company in 2023] to focus on its stronger-growth pharmaceutical and medical device businesses." She adds: "The market was skeptical of the strategy, but it's showing accelerating earnings growth from mid-single digits to potentially high-single digits toward the end of the decade, driven by a strong pipeline of new products where it's gaining market share." She says as a result, the stock has rerated significantly over the past year. Ms. Owen notes that Johnson & Johnson is also regarded as a "dividend king," with more than 60 consecutive years of dividend growth.